|
|
|
|
| 專題 |
最後回覆 |
暱稱 |
內容 |
| 聯邦制藥國際控股有限公司 |
2014-04-24T09:43 |
財經茄呢啡 |
聯邦制藥（3933）去年純利大跌七成，僅賺4,800萬銀，但績後飆四成皆因業績似差實佳，撇除一次性項目，稅後溢利增2.8倍至4.02億元。高盛認為在胰島素及新產品推動下，今年盈利將顯著增長。以稅後溢利計，現價PE22倍，藥股來講並唔貴，計埋增長潛力，以30倍PE計，可見7.4元。 |
|
|
|
|
We've noticed you're using an ad blocker
We spend millions of dollars each year so you can access, for FREE, the highest quality real-time quotes and charts. This is made possible only thanks to the advertising on our site.
To continue using 88iv.com, please allow this domain on your ad blocker.
We are thanksful for your decisive action.
This notice will be shown again every hour.
Close This Window